Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees
References (9)
- et al.
Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency
Am. J. Med.
(1984) - et al.
Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents
Eur. J. Pharmacol.
(1993) - et al.
Renal urate transport in the chimpanzee
Am. J. Physiol.
(1971) - et al.
Renal effects of uricosuric agents in the chimpanzee
J. Pharmacol. Exp. Ther.
(1971)
Cited by (66)
Process Development of Febuxostat Using Palladium- and Copper-Catalyzed C-H Arylation
2018, Organic Process Research and DevelopmentHyperuricemia Is an Independent Risk Factor for Erectile Dysfunction
2016, Journal of Sexual MedicineCitation Excerpt :Febuxostat is a selective inhibitor of xanthine oxidase that reduces serum uric acid levels by inhibiting the transformation of hypoxanthine to xanthine and of xanthine to uric acid, and has no effect on other enzymes in purine metabolism. Febuxostat was more potent than allopurinol in inhibiting xanthine oxidase and decreasing serum uric acid levels in chimpanzees.22 In this study, there is no significant difference in body weight, level of serum testosterone, blood urea nitrogen, and creatinine among these groups, but the ICPmax/MAP in hyperuricemic rats is significantly less than that in other groups.
Trisubstituted thiophene analogues of 1-thiazolyl-2-pyrazoline, super oxidase inhibitors and free radical scavengers
2013, Bioorganic and Medicinal ChemistryCitation Excerpt :Recently one of the nonpurine inhibitor, thiazole derivative, Febuxostat (7) was approved by the European Medicines Evaluation Agency (EMEA) and Food and Drug Administration (FDA), has attracted worldwide attention.25 Scholar review article by Raj Kumar et al extensively covered all patent survey for xanthine oxidase inhibitors including nonpurine analogues.26 Kavitha et al. reported substituted iminothiazoles as possible antioxidant agents (8).27
Novel thiazolo-pyrazolyl derivatives as xanthine oxidase inhibitors and free radical scavengers
2012, International Journal of Biological MacromoleculesCitation Excerpt :However use of purine analog leads to development of symptoms for Stevens–Johnson syndrome and DRESS (Drug Rash with Eosinophylia and Systemic Symptoms) [12,13] therefore extensive research has been done to report non purine analogs for XO inhibition. Recently one of the non purine inhibitor-Febuxostate (6)-that was approved by the European Medicines Evaluation Agency (EMEA) and Food and Drug Administration (FDA), has attracted worldwide attention [14]. Scholar review article by Raj Kumar et al. extensively covered all patent survey for xanthine oxidase inhibitors including non purine analogs [15].
Xanthine oxidase inhibitor treatment of hyperuricemia
2012, Gout and Other Crystal ArthropathiesXanthine oxidase inhibitor treatment of hyperuricemia
2011, Gout and Other Crystal Arthropathies: Expert Consult: Online and Print